{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:54:14Z","timestamp":1791147254964,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.radonc.2010.04.004","type":"journal-article","created":{"date-parts":[[2010,5,6]],"date-time":"2010-05-06T08:31:34Z","timestamp":1273134694000},"page":"292-297","source":"Crossref","is-referenced-by-count":13,"title":["Multicentre phase I\u2013II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study"],"prefix":"10.1016","volume":"95","author":[{"given":"Adalsteinn","family":"Gunnlaugsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pehr","family":"Lind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bengt","family":"Glimelius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Johnsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2010.04.004_bib1","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/sj.bjc.6603719","article-title":"Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation\/combined modality therapy","volume":"96","author":"Sultana","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2010.04.004_bib2","first-page":"219","article-title":"Multimodality treatment with helical tomotherapy intensity modulated radiotherapy, capecitabine, and photodynamic therapy is feasible and well tolerated in patients with hilar cholangiocarcinoma","volume":"2","author":"Baisden","year":"2008","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.radonc.2010.04.004_bib3","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ijrobp.2006.05.061","article-title":"External-beam radiotherapy for localized extrahepatic cholangiocarcinoma","volume":"66","author":"Ben-David","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2010.04.004_bib4","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/02841860500247552","article-title":"In vitro radiosensitization by oxaliplatin and 5-fluorouracil in a human colon cancer cell line","volume":"44","author":"Kjellstrom","year":"2005","journal-title":"Acta Oncol"},{"key":"10.1016\/j.radonc.2010.04.004_bib5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.ejca.2008.11.017","article-title":"Multicentre phase II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable colorectal cancer: The CORGI-L study","volume":"45","author":"Gunnlaugsson","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2010.04.004_bib6","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1200\/JCO.2006.08.3675","article-title":"Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer","volume":"25","author":"Rodel","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2010.04.004_bib7","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1093\/annonc\/mdi406","article-title":"Phase II study of preoperative oxaliplatin, capecitabine and external beam radiotherapy in patients with rectal cancer: the RadiOxCape study","volume":"16","author":"Machiels","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2010.04.004_bib8","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1002\/cncr.23810","article-title":"Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer","volume":"113","author":"Xiong","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2010.04.004_bib9","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bjc.6604178","article-title":"Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial","volume":"98","author":"Nehls","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2010.04.004_bib10","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0360-3016(99)00559-3","article-title":"Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy","volume":"47","author":"Trotti","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2010.04.004_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumours","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2010.04.004_bib12","series-title":"The statistical analysis of failure time data","author":"Kalbfleisch","year":"1980"},{"key":"10.1016\/j.radonc.2010.04.004_bib13","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/PPO.0b013e31813c12b8","article-title":"Phase II study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: up-regulation of thymidine phosphorylase","volume":"13","author":"Saif","year":"2007","journal-title":"Cancer J"},{"key":"10.1016\/j.radonc.2010.04.004_bib14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.bjc.6603900","article-title":"Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer","volume":"97","author":"Goldstein","year":"2007","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2010.04.004_bib15","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1016\/j.ijrobp.2004.01.035","article-title":"5-fluorouracil-based chemoradiation in unresectable pancreatic carcinoma: phase I\u2013II dose-escalation study","volume":"59","author":"Morganti","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2010.04.004_bib16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ijrobp.2004.12.074","article-title":"A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282","volume":"62","author":"Cohen","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2010.04.004_bib17","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1080\/02841860701592384","article-title":"Efficacy of preoperative radiochemotherapy in patients with locally advanced pancreatic carcinoma","volume":"47","author":"Lind","year":"2008","journal-title":"Acta Oncol."},{"key":"10.1016\/j.radonc.2010.04.004_bib18","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1093\/annonc\/mdn281","volume":"19","author":"Chauffert","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2010.04.004_bib19","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2007.13.9014","article-title":"Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial","volume":"26","author":"Small","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2010.04.004_bib20","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF02698046","article-title":"Concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer","volume":"24","author":"Chengiz","year":"2007","journal-title":"Med Oncol"},{"key":"10.1016\/j.radonc.2010.04.004_bib21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/030089160609200603","article-title":"Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer","volume":"92","author":"Kurt","year":"2006","journal-title":"Tumori"},{"key":"10.1016\/j.radonc.2010.04.004_bib22","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/S0360-3016(01)02806-1","article-title":"Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer","volume":"53","author":"Shinchi","year":"2002","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2010.04.004_bib23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/annonc\/mdm467","article-title":"Capecitabine plus oxaliplatin (CapOx) versus capecitabine plus gemcitabine (CapGem) versus gemcitabine plus oxaliplatin (mGemOx): final results of a multicenter randomized phase II trial in advanced pancreatic cancer","volume":"19","author":"Boeck","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2010.04.004_bib24","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/sj.bjc.6604178","article-title":"Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial","volume":"98","author":"Nehls","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2010.04.004_bib25","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/cncr.22735","article-title":"Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy","volume":"110","author":"Krishnan","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2010.04.004_bib26","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.24302","article-title":"Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma","volume":"115","author":"Reni","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2010.04.004_bib27","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S1470-2045(08)70001-9","article-title":"CA19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial","volume":"9","author":"Hess","year":"2008","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.radonc.2010.04.004_bib28","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/MPA.0b013e31816d8185","article-title":"Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy","volume":"37","author":"Wong","year":"2008","journal-title":"Pancreas"},{"key":"10.1016\/j.radonc.2010.04.004_bib29","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1200\/JCO.2006.08.2644","article-title":"ASCO 2006 of recommendations for the use of tumour markers in gastrointestinal cancer","volume":"24","author":"Locker","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814010002306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814010002306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T09:57:06Z","timestamp":1591264626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814010002306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S0167814010002306"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2010.04.004","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}